American Radium Society Appropriate Use Criteria for the use of liver‐directed therapies for nonsurgical management of liver metastases: Systematic review and guidelines
Christopher L. Hallemeier(Mayo Clinic), Suzanne Russo(Case Western Reserve University), William Small(Northwestern University), J. Eva Selfridge(University Hospitals of Cleveland), Timothy J. Kennedy(Memorial Sloan Kettering Cancer Center), Percy Lee(City Of Hope National Medical Center), Navesh Sharma(Penn State Milton S. Hershey Medical Center), Leila T. Tchelebi(Donald & Barbara Zucker School of Medicine at Hofstra/Northwell), Salma K. Jabbour(Rutgers, The State University of New Jersey), Vonetta M. Williams(Memorial Sloan Kettering Cancer Center), Krishan R. Jethwa(Mayo Clinic), Edward Kim(Rutgers, The State University of New Jersey), David Liu(Bristol-Myers Squibb (Germany)), Rachit Kumar(The University of Texas MD Anderson Cancer Center), Christopher J. Anker(University of Vermont)
Cited by 10
Related Papers
Brivanib Versus Sorafenib As First-Line Therapy in Patients With Unresectable, Advanced Hepatocellular Carcinoma: Results From the Randomized Phase III BRISK-FL Study
|Journal of Clinical Oncology|2013|775
Brivanib in Patients With Advanced Hepatocellular Carcinoma Who Were Intolerant to Sorafenib or for Whom Sorafenib Failed: Results From the Randomized Phase III BRISK-PS Study
|Journal of Clinical Oncology|2013|596
Consensus Guidelines for Delineation of Clinical Target Volume for Intensity-Modulated Pelvic Radiotherapy for the Definitive Treatment of Cervix Cancer
|International Journal of Radiation Oncology*Biology*Physics|2010|458
Consensus Guidelines for Delineation of Clinical Target Volume for Intensity-Modulated Pelvic Radiotherapy in Postoperative Treatment of Endometrial and Cervical Cancer
|International Journal of Radiation Oncology*Biology*Physics|2007|415
Epidemiology of liver metastases
|Cancer Epidemiology|2020|274